Product Images Razadyne
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 15 images provide visual information about the product associated with Razadyne NDC 21695-591 by Rebel Distributors Corp, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Chemical Structure - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 01
Graph 1 - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 02
The text seems to contain information regarding a certain treatment that lasted for 13 weeks. However, the remaining text appears to be gibberish and is not readable. Therefore, a useful description cannot be generated.*
Graph 2 - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 03
The text seems to be a chart that displays the cumulative percentage of patients and ADAS-cog changes from baseline. The chart shows three different dosages: placebo, 16 my/day, and 34 my/day. On the left, there is a vertical column with percentages from 0 to 100. The bottom of the chart shows the ADAS-cog change from baseline ranging from -15 to +15. The text is not available to explain the meaning of ADAS-cog.*
Graph 3 - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 04
Graph 4 - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 05
Graph 5 - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 06
This is a graph that shows the cumulative percentage of patients based on ADAS-cog (Alzheimer's Disease Assessment Scale-Cognitive Subscale) change from baseline. The graph compares the effects of two drugs, 24 mg/day and 32 mg/day, with a placebo. The X-axis shows the change values in ADAS-cog, ranging from -10 points to +15 points, with 0 being the baseline. The Y-axis shows the cumulative percentage of patients experiencing changes within each range.*
Graph 6 - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 07
Graph 7 - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 08
Graph 8 - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 09
This is a graph displaying the cumulative percentage of patients based on the ADAS-cog change from baseline. There are data points marked at -4 points, 7 points, and -10 points, and the x-axis displays the range of change in ADAS-cog scores from -15 to +15. There is also information on the drug regimen used, with a dosage of 4 mg/day for some patients and 5 mg/day for others.*
Graph 9 - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 10
Graph 10 - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 11
Graph 11 - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 12
Graph 12 - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 13
Razadyne HBr 4mg - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 14
Razadyne 12mg - ea6968e3 6383 4ff1 8c81 e4a2fdfe749d 15
This appears to be a mixture of different medication names, dosages, and codes. There is no clear description available.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.